VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2022 | A study of talazoparib in somatic BRCA1/2 mutant MBC identified by cfDNA or tumor tissue genotyping

Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, talks on an ongoing Phase II study (NCT03990896) of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping. PAPR inhibitors are currently approved for germline BRCA1/2 HER2-positive metastatic breast cancer. However, germline BRCA mutant breast cancer only accounts for 5-10% of breast cancer. The Phase II study is examining whether the population that benefits from PARP inhibitors can be expanded upon. It had previously been demonstrated that somatic BRCA1/2 mutations can be identified by both cell-free DNA and tumor tissue genotyping in a subset of patients with metastatic breast cancer who are not germline BRCA1/2 carriers. Patients will be treated with talazoparib, a PARP inhibitor, until disease progression. At baseline and every 3 months, patients undergo CT chest, abdomen, and pelvis, and a bone scan for disease assessment. Primary aim is progression-free survival (PFS) assessed by RECIST 1.1. Secondary aims include objective response rate and toxicity assessed by NCI CTCAE v 5.0. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Vidula reports research funding from the Institution for Merck, Dachiai, Novartis, Pfizer, Radius.

Dr Vidula reports advisory board participation for Giliad, OncoSec, Aadi, TeraSera.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter